NEW YORK, Feb. 13, 2018 (GLOBE NEWSWIRE) -- Dermatomyositis (DM) is an idiopathic (disease for which cause is unknown) inflammatory disorder of skin and skeletal muscle involvement. Patients with skeletal muscle involvement have polymyositis (PM), and patients without muscle damage and typical skin lesions have amyopathic dermatomyositis. Scleromyositis is overlap syndrome associated with anti-PM-Sci antibodies. Dermatomyositis (DM) can be treated with variety of drugs few of them are:
Abatacept – It is also known as Orencia is a protein that prevents body’s immune system from attacking healthy tissues such as joints. It is a prescription medicine used to treat the symptoms of rheumatoid arthritis, also prevent joint damage caused by rheumatoid arthritis.
Baricitinib – It is an oral selective JAK1 and JAK2 inhibitor used in the treatment of rheumatoid arthritis.
Dalazatide – It is formerly known as ShK-186 is a investigational drug designed to selectively target cells that cause autoimmune diseases such as multiple sclerosis (MS), lupus erythematosus, psoriasis, rheumatoid arthritis, type 1 diabetes and inflammatory bowel disease.
Get complete access of this report: https://www.profsharemarketresearch.com/dermatomyositis-drug-market-report/
Immune globulin intravenous (IGIV)– It is a sterilized solution made from human plasma. Immune globulin contains against the infection from various diseases. GIV is used to treat primary immunodeficiency (PI), and to reduce the risk of infection in chronic lymphocytic leukemia (CLL).
IMO-8400 – It is used in the treatment of Metastatic Melanoma and Dermatomyositis.
Dermatomyositis Drug Market: Application / End User
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
- Hospital
- Medical Center
- Research Institute
- Clinics
Get free sample of this report: https://www.profsharemarketresearch.com/sample/dermatomyositis-drug-market-report-sample/
Dermatomyositis Drug Market: Product Type
- Abatacept
- Baricitinib
- Dalazatide
- Immune Globulin
- IMO-8400
Global Dermatomyositis Drug Market: Competitive Analysis
Report includes accurate analysis of key players with Market Value, Company profile, SWOT analysis. The Study constitutes of following key players in Dermatomyositis Drug Market:
- MedImmune LLC
- Neovacs SA
- Novartis AG
- Octapharma AG
- Pfizer Inc
- Eli Lilly and Company
- F. Hoffmann-La Roche Ltd
- Hope Pharmaceuticals Inc
- Idera Pharmaceuticals Inc
- KPI Therapeutics Inc
- Marathon Pharmaceuticals LLC
Buy Report: https://www.profsharemarketresearch.com/buy/dermatomyositis-drug-market-report-buy-su/
Dermatomyositis Drug Market report delivers comprehensive analysis of:
- Market Forecast for 2017-24
- Market growth drivers
- Challenges and Opportunities
- Emerging and Current market trends
- Market player Capacity, Production, Revenue (Value)
- Supply (Production), Consumption, Export, Import analysis.
- End user/application Analysis
Contact Us :
Jeet,
Email- sales@profsharemarketresearch.com
Tel- 1-877-797-7295